Novo Nordisk(US:NVO) Globenewswire·2025-09-29 14:14Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly providing misleading statements regarding its growth potential and market performance during the class period from May 7, 2025, to July 28, 2025 [7]. Allegation Details - The lawsuit claims that Novo made overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to Novo's branded alternatives [7]. - The complaint highlights that Novo's assertions about its market potential were significantly overstated, leading to investor losses when the company later lowered its sales and profit outlook [7]. Market Reaction - Following Novo's announcement on July 29, 2025, regarding lowered growth expectations for its products Wegovy and Ozempic, the company's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [7]. Next Steps - Investors who purchased Novo shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information and to discuss their legal rights [4][8].